Clinical Trial Update: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for docetaxel albumin-bound with nivolumab in head and neck squamous cell carcinoma (Phase 1/2) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• Docetaxel (Albumin Bound) (docetaxel)
• nivolumab (nivolumab)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 1, Phase 2 | Status: UNKNOWN